GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Total Inventories

MBCOF (Marvel Biosciences) Total Inventories : $0.00 Mil (As of Oct. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Total Inventories?

Marvel Biosciences's total inventories for the quarter that ended in Oct. 2024 was $0.00 Mil. Marvel Biosciences's average total inventories from the quarter that ended in Jul. 2024 to the quarter that ended in Oct. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Marvel Biosciences's Net-Net Working Capital per share for the quarter that ended in Oct. 2024 was $-0.05.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Marvel Biosciences's Days Inventory for the three months ended in Oct. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Marvel Biosciences Total Inventories Historical Data

The historical data trend for Marvel Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Total Inventories Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Total Inventories
- - - - -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Marvel Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Marvel Biosciences  (OTCPK:MBCOF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Marvel Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Oct. 2024 is

Net-Net Working Capital Per Share (Q: Oct. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.06+0.75 * 0+0.5 * 0-2.407
-0-0)/44.786
=-0.05

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Marvel Biosciences's Days Inventory for the three months ended in Oct. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Oct. 2024 )/Cost of Goods Sold (Q: Oct. 2024 )*Days in Period
=0/0.008*365 / 4
=0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Marvel Biosciences's Inventory Turnover for the quarter that ended in Oct. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Oct. 2024 ) / Average Total Inventories (Q: Oct. 2024 )
=0.008 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Marvel Biosciences's Inventory to Revenue for the quarter that ended in Oct. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Oct. 2024 ) / Revenue (Q: Oct. 2024 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Marvel Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Total Inventories
Comparable Companies
TSXV:IBO XCNQ:ASEP XCNQ:LOBE TSXV:IOT XCNQ:RIZE TSXV:XRTX TSX:APLI XCNQ:MBIO TSXV:QPT XCNQ:BLAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.